The financials
Krystal Biotech, Inc. by the numbers
Krystal Biotech, Inc. (KRYS) reported revenue of $119M in Q2 2026 (quarter ended June 30, 2026), up 24% from the same quarter a year earlier. That came with net income of $55M (46% of revenue). For the full year FY2025, revenue was $389M (+34% year on year) and net income $205M. Its largest region in 2026-Q1 was US at $87M, 75% of the disclosed total, just ahead of Europe at 18%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $119M | $96M | +24% |
| Operating income | $58M | $39M | +48% |
| Net income | $55M | $38M | +43% |
| Diluted EPS | $1.79 | $1.29 | +39% |
| Geographic | Revenue | Share |
|---|---|---|
| US | $87M | 75% |
| Europe | $21M | 18% |
| JP | $8.2M | 7.0% |
Business Segments
Revenue split by geographic segment, from SEC XBRL filings.
Latest period: Q1 2026Total $116.4M (+32%)
Segment Latestquarter on quarteryear on year
- US$87.5M$87.5MQoQ -0.79%year on year -0.79%-0.79%-0.79%
- Europe$20.7M$20.7MQoQ -year on year ---
- JP$8.2M$8.2MQoQ -year on year ---